Drug Trial Radar · NCT02579044
Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
80
Planned (sponsor's estimate)
Start
Dec 2015
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Boston Children's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 months, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utilizing the Clinical and Translational Study Unit (CTSU) at Boston Children's Hospital. Lonafarnib will be administered at doses previously established in the pediatric population and in this population of progeria subjects. This study will first determine the dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD) of everolimus when administered in combination with lonafarnib. It will then determine the efficacy of everolimus when administered at its MTD in combination with lonafarnib for disease in progeria.
Conditions
- Progeria
Interventions
Everolimus and lonafarnibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum-tolerated dose (MTD) of everolimus when administered orally in combination with lonafarnib in subjects with progeriaTime frame: 12 Months
- Number and type of dose-limiting toxicities when everolimus and lonafarnib are administered in combination to children with progeriaTime frame: 12 Months
- Annual increase in weight gainTime frame: 24 Months
- Change in pulse wave velocity (PWV)Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Boston Children's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.